One of the biggest elephants in Merck's clinic is anacetrapib. In Phase III studies that are not projected to read out until 2016/17, it sits hoovering up R&D dollars in a once-hyped cardiovascular space – CETP inhibition – that has fallen out of favor following high-profile late-stage failures at rival pharma powerhouses.
Merck is a lonely hunter in CETP field
One of the biggest elephants in Merck's clinic is anacetrapib. In Phase III studies that are not projected to read out until 2016/17, it sits hoovering up R&D dollars in a once-hyped cardiovascular space – CETP inhibition – that has fallen out of favor following high-profile late-stage failures at rival pharma powerhouses.
More from Japan
More from Focus On Asia
• By
Heads of Novartis Biomedical, World Economic Forum and Indian majors like Sun Pharma’s SPARC, among others, discuss generative AI in drug discovery along with pointers for India to leapfrog the R&D process
• By
Lilly’s Mounjaro arrives in India, with the 2.5mg vial priced at under $41 in a market that has over 100 million diabetics and increasing obesity rates. Will the product see sharp demand like in China, carving out a chunk of the pie ahead of the potential arrival of semaglutide generics and could there be concerns of ‘suitcase' exports?
• By
South Korea's LigaChem is kickstarting a growth and globalization drive through a potential future acquisition of UK ADC player IKSUDA.